Establishment of phosphatidylinositol 3-kinase inhibitor-resistant cancer cell lines and therapeutic strategies for overcoming the resistance

Defining the pathway to insulin-like growth factor system targeting in cancer

(2010) Steven A. Rosenzweig et al.   BIOCHEMICAL PHARMACOLOGY

Correlating Phosphatidylinositol 3-Kinase Inhibitor Efficacy with Signaling Pathway Status:In silicoand Biological Evaluations

(2010) Shingo Dan et al.   CANCER RESEARCH

A Chromatin-Mediated Reversible Drug-Tolerant State in Cancer Cell Subpopulations

(2010) Sreenath V. Sharma et al.   CELL

Targeting the Type I Insulin-Like Growth Factor System for Breast Cancer Therapy

(2010) Deepali Sachdev   CURRENT DRUG TARGETS

The potential role of insulin-like growth factor receptor inhibitors in the treatment of advanced non-small cell lung cancer

(2010) Cesare Gridelli et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS

The proliferating role of insulin and insulin-like growth factors in cancer

(2010) Emily Jane Gallagher et al.   TRENDS IN ENDOCRINOLOGY AND METABOLISM

Discovery of Drug-Resistant and Drug-Sensitizing Mutations in the Oncogenic PI3K Isoform p110α

(2008) Eli R. Zunder et al.   CANCER CELL

Hepatocyte Growth Factor Induces Gefitinib Resistance of Lung Adenocarcinoma with Epidermal Growth Factor Receptor-Activating Mutations

(2008) S. Yano et al.   CANCER RESEARCH

Mechanisms of Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer

(2008) J. A. Engelman et al.   CLINICAL CANCER RESEARCH

Implications of insulin-like growth factor-I for prostate cancer therapies

(2008) Satoko Kojima et al.   INTERNATIONAL JOURNAL OF UROLOGY